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Abstract
Although the expression of PECAM-1 (CD31) on vascular and haematopoietic cells within the bone marrow
microenvironment has been recognized for some time, its physiological role within this niche remains unexplored. In
this study we show that PECAM-1 influences steady state hematopoietic stem cell (HSC) progenitor numbers in the
peripheral blood but not the bone marrow compartment. PECAM-12/2 mice have higher levels of HSC progenitors in the
blood compared to their littermate controls. We show that PECAM-1 is required on both progenitors and bone marrow
vascular cells in order for efficient transition between the blood and bone marrow to occur. We have identified key roles for
PECAM-1 in both the regulation of HSC migration to the chemokine CXCL12, as well as maintaining levels of the matrix
degrading enzyme MMP-9 in the bone marrow vascular niche. Using intravital microscopy and adoptive transfer of either
wild type (WT) or PECAM-12/2 bone marrow precursors, we demonstrate that the increase in HSC progenitors in the blood
is due in part to a reduced ability to migrate from blood to the bone marrow vascular niche. These findings suggest a novel
role for PECAM-1 as a regulator of resting homeostatic progenitor cell numbers in the blood
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Introduction
The bi-directional movement of HSCs between the vascular
niche and the circulation is an area of intense study. Alterations in
integrins, chemokine receptors and the activation of proteases
have all been demonstrated to be required for HSC mobilization
and subsequent engraftment to occur efficiently [1,2] Of particular
importance is the localised concentration of CXCL12 (SDF-1a) in
the bone marrow as this is the principal chemokine to which HSCs
respond[3]. This chemokine not only acts as a chemoattractant for
HSCs, but ligation of its receptor, CXCR4, induces integrin
upregulation and promotes HSC survival[4–7]. Modulation of the
CXCR4/CXCL12 interaction on HSCs has been shown to
directly affect HSC migration and function[8].
Platelet Endothelial Cell Adhesion Molecule-1 (PECAM-1/
CD31) is a 130kDa glycoprotein and member of the immunoglob-
ulin superfamily, which is expressed on many haematopoietic and
endothelial cells[9]. PECAM-1 is expressed on the surface of various
cells of the haematopoietic lineage[10–12], however the function of
PECAM-1, if any, on haematopoietic progenitor cells and the bone
marrow vasculature remains to be fully elucidated. It has been
observed that expression of PECAM-1 decreases following the
emigration of CD34+ cells and monocytes[13] from the bone
marrow to the blood[13,14]. The expression of PECAM-1 on
CD34+ cells, like that on endothelial cells, has been demonstrated to
provide an anti-apoptotic signal[15,16], with ligation of PECAM-1
enhancing VLA-4 mediated adhesion[17], and blocking antibodies
to PECAM-1 reducing transendothelial migration[18,19].
We and others have recently discovered a novel role for
PECAM-1 in regulating CXCR4 dependent megakaryocyte
migration within the bone marrow vascular niche[20,21]. The
expression of PECAM-1 on HSCs and the bone marrow
vasculature, together with the well established role for PECAM-
1 in regulating cell adhesion, migration and activation in cells of
haematopoietic origin prompted us to examine whether PECAM-
1 could regulate HSC function in the bone marrow vascular niche.
We observed that PECAM-1 regulates steady state progenitor
cell numbers in the peripheral blood but not the bone marrow
compartment. PECAM-12/2 mice exhibited an increase in the
number of circulating progenitor cells in the resting state,
compared to littermate wild type control mice. Using intra-vital
microscopy, we found that loss of PECAM-1 on either bone
marrow progenitors or vascular cells resulted in the failure of cells
to migrate across the bone marrow vasculature leading to their
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accumulation within the peripheral circulation. We have identified
an intrinsic migration defect of HSCs to CXCL12 as well as
increased levels of MMP-9 in the bone marrow of PECAM-12/2
mice, suggesting that factors intrinsic to both the HSC and bone
marrow vascular niche account for the increase in circulating
progenitor numbers in the blood of PECAM-12/2 mice.
Our results suggest that PECAM-1 plays an important role in
integrating CXCL12 dependent signals involved in HSC accu-
mulation within the bone marrow, such that loss of PECAM-1
prevents effective bidirectional movement of HSCs between the
blood and bone marrow compartments.
Materials and Methods
Mice and bone marrow collection
Age and sex matched wild type (WT) and PECAM-12/2
littermates on the C57BL6J background were bred from
heterozygotes. All mice were maintained at the Biomedical
services unit at the University of Birmingham, according to Home
Office regulations. Bone marrow cells were flushed from femurs
and tibias of 6–9 week old mice, and resuspended in ACK lysis
buffer (0.15M NH4Cl; 1 mM KHCO3; 0.1 mM Na2EDTA
pH7.3) to lyse mature erythrocytes before use in subsequent assays.
Flow Cytometric Analysis
Bone marrow cell populations were quantified and phenotyped
using a CyAn ADP flow cytometer (Dako, Ely, UK). The following
monoclonal antibodies were used: anti-mouse lineage panel-APC,
anti-c-Kit-RPE, anti-Sca-1-PE/Cy7, anti-CD127-Pacific Blue (all
BD Biosciences), anti-CD34-FITC, anti-CD16/CD32-PE/Cy5 and
biotinylated anti-CD135 (all eBioscience, Insight Biotechnology,
UK). Biotinylated antibodies were visualised with streptavidin-APC/
Cy7 (BD Bioscience). Chemokine receptor and integrin expression
was demonstrated using biotinylated anti-CXCR4, anti-CD49d or
FITC labelled anti-CD18, CD29 and CD61 antibodies (all BD
Biosciences). The HSC population was defined as c-Kit+, Sca-1+ but
lineage2 (KSL population), and at least 16106 total bone marrow
events were analysed per sample . KSL cells were purified by double
FACS sorting using a high speed cell sorter (Dako, Ely, UK).
Cell Migration Assays
Transwell chamber assays were performed in transwell buffer
(RPMI supplemented with 2 mM glutamine, 100units/ml peni-
cillin, 100 mg/ml streptomycin and 0.5% Fraction V BSA; all
Sigma-Aldrich, UK). Recombinant murine CXCL12 (Peprotech
EC, UK) was added to the bottom chamber at 200–500 ng/ml.
Cell suspensions were isolated and resuspended at 26106/ml in
transwell buffer, before adding 100 ml to the top chamber. Assays
ran for 4 hours before collecting and quantifying the cells migrated
into the bottom chamber using a fixed volume count flow
cytometry protocol (Epics XL, Coulter). PI was added to each tube
to discriminate dead cells and debris.
Dunn chamber assays were performed using HSCs purified by
immunomagnetic bead selection. Whole bone marrow was firstly
negatively depleted with lineage specific beads (Lineage Cell
Depletion Kit, Miltenyi Biotech) according to the manufacturer’s
instructions. The resulting cells were then positively selected using
CD117 Microbeads (Miltenyi Biotech) and rested overnight in
StemCell Pro media (supplemented with 2.6% serum replacement,
2 mM glutamine, 100 units/ml penicillin, 100 mg/ml streptomycin),
and containing factors to promote survival and inhibit differentiation
(50 ng/ml recombinant SCF and 10 ng/ml recombinant Flt-3L;
Peprotech EC, UK). Dunn chambers were performed as previously
described[20,22], using 26105 cells per assay.
G-CSF Induced CFC Mobilisation
The induced mobilisation of bone marrow HSCs was
performed using a protocol adapted from Petit et al.[23]. Briefly,
mice received a daily subcutaneous injection of G-CSF (Neupo-
gen, Amgen Inc, USA; 300 mg/kg in 100 ml PBS) for 4
consecutive days and were sacrificed 6 hours after the last
injection. Peripheral blood was collected by cardiac puncture into
heparinised tubes, and leg bones removed. The quantification of
CFCs in bone marrow and peripheral blood was performed using
MethoCult GF media (M3434, Stemcell Technologies, UK),
according to the manufacturers protocol. Two independent
researchers counted all colonies on duplicate plates for each
condition tested at days 7 and 10.
CXCL12 ELISA
CXCL12 levels in bone marrow were measured by flushing the
femurs and tibias from one mouse with 500 mls of PBS. Cells were
centrifuged, supernatants aliquoted and frozen at 280uC. ELISAs
were performed according to the protocol published by Petit et
al.[23]. Briefly, wells of a 96-well plate were coated overnight with
50 mls of anti-CXCL12 antibody (MAb 79018, R&D Systems,
UK) at a concentration of 2 mg/ml in bicarbonate buffer (15 mM
Na2CO3; 35 mM NaHCO3 pH9.6). Wells were washed 3 times,
blocked for 1 hour with PBS/1%BSA/5% Sucrose at room
temperature, rewashed 3 times and 50 ml of sample in duplicate
wells added for 2 hours at room temperature. Recombinant
murine CXCL12 (Peprotech EC) was used to generate a standard
curve. Wells were washed 3 times and 50 mls of anti-CXCL12-
biotin capture antibody (MAb BAF310, R&D Systems, UK) at
250 ng/ml for 2 hours at room temperature. After 3 washes, 50 ml
of streptavidin-HRP was added for 20 mins at room temperature,
washed for a further 3 times, and incubated for 20–30 mins with
50 ml of TMB substrate solution (Sigma-Aldrich, UK). Reactions
were stopped with 50 ml of 2M H2SO4 and wells read at 450 nm
on an optical plate reader. All samples analysed were quantified
for protein concentration and results expressed as ng/ml CXCL12
per mg/ml protein in solution.
Indirect Immunofluorescence staining and confocal
microscopy
Cryosections (8 mm) of mouse femur were fixed in acetone and
blocked with 5% mouse and 5% goat serum in PBS. Sections were
stained with the following antibodies: From Ebioscience anti-
endoglin-biotin (clone MJ7/18) and anti-VCAM-1-FITC (clone
429). Anti-CXCL12 (clone 79018) was from R&D Systems.
Secondary reagents were anti-FITC-Alexa 488 (Molecular
Probes), goat anti-mouse IgG1-TRITC (Southern Biotech) and
Streptavidin-Cy5 (Jackson Immuno Research). Cell nuclei were
visualised using Hoescht 33258. A Zeiss confocal LSM 510
microscope (Zeiss, Germany) was used to visualize staining with
images captured and processed using the Zeiss LSM Image
Examiner software (Zeiss).
Intravital Imaging of the Bone Marrow Microcirculation
Intravital observations of the bone marrow were made using the
skull window preparation previously described by Mazo and
colleagues[24]. All procedures were undertaken with United
Kingdom Home Office approval in accordance with the Animals
(Scientific Procedures) Act of 1986 (Project Licence No: 40/2749).
Anaesthesia was induced with an intraperitoneal injection
ketamine (100 mg/kg Vetalar; Pharmacia and Upjohn Ltd, UK)
and 2% xylazine (20 mg/kg; Millpledge Pharamaceuticals, UK).
Cannulae were inserted in the trachea to facilitate spontaneous
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respiration and in the left carotid artery to provide a route for
administration of additional anaesthesia as required. The carotid
cannula also provided access for administration of fluorescently
labelled albumin and cells. The scalp was incised in the midline
and the frontoparietal skull was exposed carefully avoiding tissue
damage to the area. A plastic ring was placed to maintain exposure
of the incision and to allow application of sterile saline to prevent
drying of the tissue. The animal was immobilised in a custom
made stereotactic frame.
Animals were transferred to the stage of a motorized Olympus
BX-61WI microscope equipped with a water immersion objective
(Olympus UmplanFI 10x/0.30w). The microvessels were identi-
fied after administration of FITC-BSA (0.1 mg/ml, Sigma, UK).
Following this, whole bone marrow cells were isolated from femurs
as previously described, labelled with 5 mM CFSE (Molecular
Probes, Invitrogen, Paisley, UK) and introduced systematically.
Digital images were collected using a high capture rate Sensicam
CCD camera (the Cooke Corporation, USA). A high performance
GEN III image intensifier (Videoscope Int. Ltd., USA) incorpo-
rated between the microscope and camera amplified light 1000-
fold, allowing visualization of low fluorescent intensities. Images
were collected using Slidebook software (Intelligent Imaging
Innovations, USA) and stored as permanent digital images for
subsequent off line analysis. One pre-selected field of view was
recorded for 5 mins after administration of bone marrow cells to
allow quantification of rolling cells. To quantify adherent cells, a
second recording of the entire exposed left frontoparietal area was
captured one hour post-injection. Cells adherent to the microves-
sels for ,30 seconds were considered adherent.
Zymography
Bone marrow flushes were spun down to remove cell debris and
quantified for protein content by BCA assay (Pierce, UK). 20 mg
total protein was prepared in nondenaturing loading buffer and
size fractionated in 10% SDS-polyacrylamide gel containing
1 mg/ml collagen. Gels were washed twice in 2.5% Triton X-
100 and incubated overnight at 37uC in 10 mM Tris-HCl buffer,
pH 7.5 containing 1.25% Triton X-100, 5 mM calcium chloride
and 1 mM zinc chloride. Gels were fixed in 50% methanol and
10% acetic acid containing 0.25% Coomassie Blue for 2 hours,
and the digested bands revealed by destaining with 25% methanol
and 10% acetic acid solution. Gels were scanned and quantified as
previously described[25].
Statistical Analysis
All experiments were performed a minimum of three times and
images shown are representative of one experiment performed.
Data are shown as mean6S.D. and statistical analysis was
performed using 2-tailed Student’s t test. Probability values of P
below 0.05 were considered to be statistically significant.
Results
Phenotypic analysis of HSC numbers and differentiation
in the bone marrow of PECAM-12/2 mice
We first examined HSC cell numbers in the bone marrow of
PECAM-1 deficient mice compared to age and sex matched
littermate controls. Total bone marrow cell numbers were the
same in bone marrow flushes from WT littermates and PECAM-
12/2 mice (Figure 1A). The number of HSCs, defined by KSL
staining, in PECAM-1 deficient mice was not significantly different
compared to WT littermate controls (WT 0.16%60.14, KO
0.21%60.2, n= 21) (Figure 1B). A similar observation was made
using side population analysis[26] (data not shown). This suggests
that bone marrow cell homeostasis is maintained upon PECAM-1
deletion.
We next examined whether there were differences in progenitor
subsets in the bone marrow based on previously published
phenotyping information[27–29]. Table 1 shows there were no
significant differences in the numbers of the commonly described
subsets of HSC progenitors in the WT and PECAM-12/2, mice
suggesting that loss of PECAM-1 does not drive differentiation
into one particular haematopoietic lineage. Similar findings were
observed using the recently described protocols to differentiate
HSCs based on their expression of the SLAM family receptors
CD48 and CD150[30] (data not shown).
Increased numbers of functional progenitor cells in the
steady state circulation of PECAM-12/2 mice
We next examined whether loss of PECAM-1 affected the
accumulation of HSC progenitors in the peripheral blood, using
colony forming assays (Figure 1C). We observed a significant
increase in the number of CFCs in the blood of PECAM-12/2
mice in steady state conditions compared to WT littermate
controls. Following enforced mobilization with G-CSF there were
no differences in either the number of CFCs in the blood
(Figure 1C) or the percentage of KSL cells in the bone marrow in
both WT and PECAM-12/2 mice (data not shown), suggesting
that loss of PECAM-1 selectively affects progenitor cells numbers
in the steady state circulation, but does not affect their ability to be
actively mobilized.
PECAM-12/2 HSC cells demonstrate impaired migration
to CXCL12 (SDF-1a)
CXCL12 (SDF-1a) is critically involved in the regulation of HSC
accumulation and migration, both within the bone marrow niche
and between the bone marrow and the peripheral circulation[5].
We therefore examined the ability of HSCs from PECAM-12/2
and littermate controls to migrate to CXCL12. Purified KSL cells
were isolated from whole bone marrow by cell sorting ($99%
purity), and migration to CXCL12 assessed using a Transwell
assay. PECAM-12/2 KSL cells displayed a reduced capacity to
migrate to CXCL12 compared to WT littermate controls
(Figure 2A). A similar effect was observed using whole bone
marrow extracts, isolated thymocytes and purified mature CD3+
splenic T cells suggesting that the altered migration response to
CXCL12 is an intrinsic property of the PECAM-12/2 HSCs, and
that the defect persists throughout haematopoietic development in
lymphocytes. Whole bone marrow cell preparations were also
assayed using other chemotactic agents including MCP-1, KC,
RANTES and IL-8, but no difference in the migratory capacity of
WT and PECAM-12/2 was observed to these chemotactic agents
(data not shown). Thus the defect in migration of PECAM-12/2
bone marrow cells appears to be specific to CXCL12.
These findings using static transwell assays were confirmed using
Dunn chamber migration assays to assess the speed and direction of
cell migration. Lineage negative, CD117+ progenitor cells were
allowed to migrate on fibronectin, a major extracellular matrix
component of bone marrow[31], to a gradient of CXCL12.
Individual line tracings and circular histograms (Figure 2B) show
the overall speed and direction of migration, and demonstrates the
variation in the rate of movement of individual cells. PECAM-12/2
cells exhibited a more random migratory pattern consistent with loss
of CXCR4 polarisation which has been observed in other PECAM-
12/2 cell types[20]. 88% of WT cells move to within a 120u arc
facing the CXCL12 source, whereas only 52% of PECAM-12/2
CD117+ cells do so. The cell traces also demonstrate that PECAM-
PECAM-1 Regulates HSC Numbers
PLoS ONE | www.plosone.org 3 June 2008 | Volume 3 | Issue 6 | e2338
12/2 cells move relatively short distances before changing direction,
suggesting that they also lack directional persistence (Figure 2C).
To determine if the reduced migration to CXCL12 in the
PECAM-12/2 HSCs was due to altered expression of cell surface
receptors on the HSCs, key molecules involved in migration to
CXCL12 and in migration on cell matrices were quantified using
flow cytometry (Figure 2D). Importantly, the expression of
CXCR4 and a range of integrin receptors were the same on
WT and PECAM-12/2 HSC, suggesting that the reduced
response to CXCL12 by PECAM-12/2 HSCs is an intrinsic
defect, and not due lack of expression of the CXCR4 receptor.
Despite the slightly increased b1 integrin expression on PECAM-
12/2 cells, this integrin is in the normal activation state as shown
by expression of the activation epitope specific antibody
9EG7[32,33]. Thus the defect in migration of the PECAM-12/2
does not appear to be due to inappropriate activation of b1 integrins
following PECAM-1 deletion.
Normal expression of CXCL12, but increased MMP-9
expression in the bone marrow microenvironment in
PECAM-12/2 mice
PECAM-1 is expressed not only on cells of the haematopoietic
lineage but also on blood vessels in the bone marrow. This raised
the possibility that factors intrinsic to bone marrow vascular cells
might also contribute to the increase HSC numbers in the blood of
PECAM-12/2 mice. To address this question, total levels of
CXCL12 present in the bone marrow were quantified by ELISA
Figure 1. Analysis of haematopoietic progenitors in the bone marrow and peripheral blood. (A) There was no significant difference in
total bone marrow cell numbers between PECAM-12/2 and WT mice (n = 21). (B) The percentage of KSL cells in the bone marrow cellular pool was
measured by flow cytometry, and no significant difference was observed (n = 22 pairs). Bars in (A) and (B) represent mean values, and in both cases no
significant difference was observed. (C) The number of colony forming cells (CFCs) in peripheral blood of mice was determined using methylcellulose
assays. Data shown is the mean6S.D. of 6 pairs of littermate mice, **p = 0.008. To measure the ability of PECAM-12/2 HSCs to mobilise from the bone
marrow, mice were treated with a daily injection of G-CSF. No significant difference in the number of CFCs released into the peripheral blood was
found. (n = 6 pairs of littermates).
doi:10.1371/journal.pone.0002338.g001
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(Figure 3A). CXCL12 levels were not statistically different between
PECAM-12/2 and WT littermates, suggesting that the increased
number of CFCs in the blood is unlikely to be due to loss of
CXCL12 in the bone marrow. Levels of stem cell factor (SCF),
another important factor in HSC release into the circulation[34]
were also measured and these were similar between PECAM-12/2
and WT mice (data not shown).
In addition, immunofluorescence microscopy was performed on
cryofrozen longitudinal sections of bone marrow to see if the
localization of CXCL12 was different between WT and PECAM-
12/2 mice. Figure 3B shows representative images of sections
stained for CXCL12, using endoglin (CD105) as a vascular marker,
and VCAM (CD106) as a stromal cell marker. Confocal microscopy
gave similar results to the ELISA data, with no clear difference in
levels or spatial localization of CXCL12. There was no significant
difference in VCAM expression or localization. This implies that
CXCL12 expression and localization in the bone marrow vascular
niche is broadly similar, compared to WT littermates.
Functional levels of MMP-9, a protease which is important in
HSC homeostasis and release from the BM[2], were quantified
using in gel zymography. MMP-9 has been previously shown to be
associated with PECAM-1 activation[35], and other MMPs have
been found to be increased in other PECAM-12/2 cell types[36].
PECAM-12/2 bone marrow had significantly increased levels of
MMP-9 compared to WT littermates (Figure 3C), suggesting that
the loss of PECAM-12/2 in the bone marrow might contribute to
the defects we observed.
HSC accumulation in the peripheral blood of PECAM-12/2
mice in vivo is due to factors intrinsic to HSC progenitor cell
migration as well as blood vessel function
In order to determine whether the increase in HSC progenitors
in the blood of PECAM-12/2 mice could be explained by a defect
in the ability of these cells to adhere and migrate between the
blood compartment and the bone marrow vasculature, we used an
intra-vital skull window model to directly observe progenitor cells
interacting with bone marrow blood vessels[24]. Bone marrow
cells were fluorescently labelled with CFSE and injected into the
carotid artery. Bone marrow blood vessels were identified by pre-
administration of FITC labelled albumin (Figure 4A). Represen-
tative images show CFSE labelled cells adhering to the smaller
sinusoidal vessels in the skull; regions which are thought to be
similar to those in the bone marrow. The cells imaged are located
on the luminal surface of the endothelial cells, having been
captured and tethered from flow.
One hour post injection, the number of cells adherent to the
visualised vessels was quantified (Figure 4B). Using various
combinations of host animals with donor cells, we observed that
both PECAM-12/2 and WT cells could adhere directly to bone
marrow vessels. However genetic deletion of PECAM-1 on
transferred cells or recipient bone marrow lead to an increase in
the number of cells accumulating on blood vessels in the bone
marrow vasculature. Although not statistically significant, this
suggests that deletion of PECAM-1 from either the host
vasculature or donor HSC results in a delay in the ability of the
bone marrow cells to cross endothelium as measured by their
increased adherence to the bone marrow lumen. A similar
observation was made when PECAM-12/2 bone marrow cells
were transferred into PECAM-12/2 mice, suggesting that deletion
of PECAM-1 on either the bone marrow precursor cells or the
vasculature is sufficient to lead to observed phenotype, consistent
with loss of homophilic interactions between PECAM-1 expressed
on HSC and the bone marrow vasculature.
Discussion
In order to move between the bone marrow and blood
compartments, bone marrow progenitor cells have to migrate across
vascular cells, which permit the bidirectional movement of
haematopoietic cells between these two compartments. Although
PECAM-1, expressed on blood and vascular cells has been shown to
play an important role in regulating the movement of leucocyte
subsets into peripheral tissues, it has remained unclear whether
PECAM-1 plays a similar role in regulating progenitor cell migration
across the bone marrow vasculature. In this study we describe a
novel role for PECAM-1 in regulating progenitor cell numbers in the
peripheral blood and show that part of the mechanism by which this
occurs is via the effect on CXCL12 dependent HSC migration as
well as an increase in MMP-9 expression upon deletion of PECAM-
1 on bone marrow vascular cells.
Our data demonstrates that loss of PECAM-1 does not affect
the homeostatic balance of HSCs in the bone marrow, resulting in
equivalent numbers of both KSL and total mature cells of all
lineages. These observations are at odds with those reported by
Wu et al[21], who observed a statistically significant hyper cellular
marrow in the PECAM-12/2 mice. While we did observe a wider
range of KSL numbers in the PECAM-12/2 mice this was not
significantly different to WT mice. Further analysis of our data
showed that six pairs of mice pairs had less KSL cells defined as
KO bone marrow having #0.9 fold of WT KSL numbers. Nine
Table 1. Flow cytometric analysis of haematopoietic progenitor subsets.
Subset Phenotype % Total BM
Dormant HSC (LT-HSC) Lin2 CD342 CD1352 Sca-1+ CD117+ WT 0.009660.0036 KO 0.011760.0047
Activated HSC (ST-HSC) Lin2 CD34+ CD1352 Sca-1+ CD117+ WT 0.022460.0164 KO 0.029160.0273
MPP Lin2 CD34+ CD135+ Sca-1+ CD117+ WT 0.035560.0228 KO 0.029160.0273
CLP Lin2 CD127+ Sca-1int CD117int WT 0.01460.019 KO 0.01360.015
GMP Lin2 CD1272 CD34+ CD16/32+ Sca-12 CD117+ WT 0.08160.054 KO 0.07160.052
MEP Lin2 CD1272 CD342 CD16/322 Sca-12 CD117+ WT 0.20160.154 KO 0.24160.153
CMP Lin2 CD1272 CD34+ CD16/32low Sca-12 CD117+ WT 0.10060.087 KO 0.11760.059
Bone marrow cells were isolated and subgroups of haematopoietic progenitor cells were identified by flow cytometry from 6–8 week old mice. Data shown is from at
least 6 littermate pairs. LT-HSC Long-Term HSC; ST-HSC Short-Term HSC; MPP Multipotent Progenitor; CLP Common Lymphoid Progenitor; CMP Common Myeloid
Progenitor; GMP Myelomonocytic Progenitor; MEP Megakaryocytic/Erythrocyte Progenitor. No significant difference between WT and PECAM-12/2 mice was observed
in any of the populations studied.
doi:10.1371/journal.pone.0002338.t001
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Figure 2. PECAM-12/2 HSCs demonstrate defective cell migration towards a gradient of CXCL12. (A) 0.1,16106 cells isolated from
individual PECAM-12/2 and littermate matched WT animals were placed in a transwell chamber and their ability to migrate to a gradient of CXCL12
was quantified from at least 3 pairs of mice; cell sorted KSLs (n = 3, p = 0.019), whole bone marrow (n = 7, p = 0.02), thymocytes (n = 4, p = 0.005) and
purified CD3+ T cells (n = 7, p = 0.03). (B) Dunn chambers were used to trace the migration path over one hour of 20 lineage depleted, CD117+
progenitor cells. The intersection of the x- and y-axis was taken as the starting point of each cell path, and the source of CXCL12 was at the top.
Circular histograms show the proportion of cells whose final position was located within each of 18 equal sectors (20u). (C) The net translocation
distance (displacement from start to end point) of each cell was measured (mean6S.D.; *p.0.05). (D) Expression levels of surface proteins on KSL
cells were quantified on whole bone marrow isolates by flow cytometry. Histograms I-VI are representative of at least four independent experiments,
and no significant difference in staining was observed between PECAM-12/2 (grey) and WT (black) littermate controls, except for CD29 (ii, n = 5,
*p = 0.038). Faint histograms depict the appropriate isotype controls.
doi:10.1371/journal.pone.0002338.g002
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pairs had more KSL cells defined as KO bone marrow having
$1.1 fold of WT KSL numbers. Wu et al [21], examined an
expanded KSL population based on three pairs of mice. Several
studies have reported that intrinsic natural variation between
animals warrants the use of substantial animal numbers when
comparing stem cell numbers between littermate pairs[37,38].
The differences between our data and that of Wu et al.[21] may
reflect the size of animal groups being used in each study.
Our data demonstrates that PECAM-12/2 HSCs have a
reduced ability to respond to CXCL12 gradients, which results
physiologically in an increased number of progenitors in the
peripheral circulation. CXCL12 gradients are crucially important
in regulating HSC biology in both the osteoblastic and vascular
niches of the bone marrow. CXCL12 produced by osteoblasts is
thought to not only provide survival, adhesive and proliferation
signals, but is also used in the re-homing of HSCs to the
osteoblastic niche[39,40]. G-CSF induced mobilisation of HSCs
results in a dramatic reduction of CXCL12 produced by
osteoblasts, thus losing the retention signal required to keep them
in the bone marrow[23]. The signalling mechanisms that underpin
these CXCL12 mediated effects are still to be elucidated but the
Rho GTPases, Rac1 and Rac2 has been shown to be required for
HSC mobilisation and homing[41].We have no direct evidence
that the osteoblastic niche in the PECAM-12/2 mice is abnormal,
as normal levels of CXCL12 are present in the bone marrow
(Figure 3A). We have however noted that the bone marrow of
PECAM-12/2 mice contains increased levels of MMP-9
(Figure 3C), a proteolytic enzyme which is known to inactivate
CXCL12 through cleavage of its NH2-terminal signal se-
quence[42]. Thus the increase in HSC mobilisation in the resting
state of the PECAM-12/2 could be explained by deactivation of
exogenous CXCL12 by the excess MMP-9 present in the bone
marrow, or protease cleavage of other retention factors such as
SCF, resulting in increased mobilization from the bone marrow
under steady state conditions.
Using intra vital microscopy we have found that PECAM-1 is
involved in the migration of bone marrow progenitors from the
blood to the bone marrow. We observed an increase in the
number of cells binding to the lumen of smaller sinusoidal vessels
in the skull when PECAM-1 is deleted from either the
endothelium or adoptively transferred cells. These vessels have
been previously demonstrated to be physiologically similar to the
bone marrow vasculature[24], and suggests that the PECAM-12/2
mouse has a general defect in the ability of cells to interact with both
the peripheral and bone marrow vasculature in-vivo. This observation
provides an alternative explanation as to the increase in HSC
numbers in the peripheral blood, as these cells may have a reduced
ability to traffic into the bone marrow or other tissues, resulting in an
accumulation in the peripheral blood. Unfortunately our intravital
studies are limited to using whole bone marrow isolates, as it was not
feasible to look at the trafficking of purified HSCs using this
technique due to the small numbers of cells that can be isolated and
enriched from the bone marrow.
In the vascular niche, CXCL12 can induce transmigration of
HSCs across endothelium, in a P- and E-selectin[43] dependant
process. Integrins are also important as induced deletion of either
CD29 (b1 integrin), CD49d (VLA-4) or ligands such as VCAM-1
results in increased numbers of progenitor cells in the circula-
tion[44]. The PECAM-12/2 phenotype resembles elements of
these deletion studies which also have increased number of
circulating progenitor cells, suggesting that alternative adhesion
molecules can compensate in the absence of PECAM-1 expres-
sion. We have not observed any significant differences between
PECAM-12/2 and WT cells in their ability to adhere or roll on
selectin coated surfaces in vitro (data not shown). However, as
reported in many other studies, challenged PECAM-12/2 mice
demonstrate an inflammatory response which is more aggressive
and prolonged[45–47]. Our results suggest that part of these
differences may occur because of the defect in HSC migration
between the blood and BM compartments,
It is likely that the reduced ability of PECAM-12/2 HSCs to
migrate to CXCL12 is due to loss of an intrinsic signalling
Figure 3. Effects of PECAM-12/2 deletion on the bone marrow
microenvironment. PECAM-12/2 and WT littermate bone marrow
was collected in PBS and analysed for factors important in HSC
mobilisation. (A) PECAM-12/2 bone marrow has comparable levels of
CXCL12 compared to WT littermates, as measured by ELISA (n = 13). (B)
Longitudinal sections of whole murine femora from matched pairs of
PECAM-12/2 and WT littermates were immunofluorescently stained for
components of the bone marrow microenvironment; CXCL12 (red),
VCAM-1 (green) and marrow sinusoidal vessels by endoglin (CD105,
blue). Images are representative of at least three pairs of femurs, and
images are taken at 640 magnification. (C.) In-gel zymography
demonstrated that PECAM-12/2 bone marrow flushes contained higher
levels of MMP-9. Pooled data from 6 litter matched pairs confirmed this
to be a significant difference (data shown as the mean6S.D.,
*p = 0.003).
doi:10.1371/journal.pone.0002338.g003
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pathway mediated by the cytoplasmic domain of PECAM-1. The
PECAM-1 cytoplasmic domain contains two conserved ITIM
domains, and studies have demonstrated that PECAM-1 can have
both inhibitory and activatory effects in various cell types[48]. It
has been postulated that PECAM-1 can act as a ‘‘relay post’’ for
modulating other surface receptors through sequestration of
cytoplasmic signalling molecules such as catenins, SHP-1 and
SHP-2, Src family kinases and STATs[49–54]. PECAM-1
activation can modulate integrin function in leucocytes, by
selectively activating the small GTPase Rap1[57], which may be
important for PECAM-1 mediated increase in cell migra-
tion[55,56]. The exact signalling pathway utilised by PECAM-1
is yet to be fully described in any cell type studied, including HSCs.
However, signalling intermediates known to be activated by
PECAM-1, such as Rap1, have already been reported to modulate
integrin function in HSCs[41].
Our study has revealed a novel role for PECAM-1 in the biology
of HSCs in the bone marrow and their ability to respond to a
CXCL12 gradient, which we propose results in an increased number
of progenitor cells in the peripheral circulation. Using in-vivo
imaging, we have observed a reduced ability of cells to migrate across
bone marrow vascular endothelium upon PECAM-1 deletion. We
could find no significant difference in numbers of HSCs or cells
derived from them in the bone marrow suggesting that loss of
PECAM-1 does not affect hematopoietic homeostatic mechanisms
in the bone marrow compartment in the resting state. We have
however found higher levels of MMP-9 in the bone marrow of
PECAM-12/2 mice suggesting that the vascular niche in the bone
marrow is abnormal in PECAM-12/2 mice. These findings further
support a role for PECAM-1 in modulating cellular migration and
adhesion and extend the vascular compartments regulated by
PECAM-1 to include the bone marrow vasculature niche.
Figure 4. Loss of PECAM-12/2 on either HSCs or endothelium affects cell adhesion to the bone marrow vasculature. CFSE labelled
bone marrow cells from littermates were infused into recipient mice through a canulae in the carotid artery. Vessels in the skull were visualised with
an infusion of fluorescine dye, selected fields recorded for 5 mins, and then images collected over the entire exposed vasculature 60 mins post
injection. (A) Representative images of fields of view captured. (B) The number of cells adherent to the bone marrow microvessels 60 mins post
injection in the exposed left frontoparietal area was quantified. Data shown is the mean6S.D of at least three independent experiments per
condition, but was not statistically significant using ANOVA analysis.
doi:10.1371/journal.pone.0002338.g004
PECAM-1 Regulates HSC Numbers
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2338
Acknowledgments
We would like to thank Dr Rudi Manz for his assistance in preparing bone
marrow sections, and Dr Paloma Garcia and Miss Mary Clarke for their
advice and support.
Author Contributions
Conceived and designed the experiments: GN SE CB ER SF TD SW JF.
Performed the experiments: ER YZ TD ER SL ZA TH NK. Analyzed the
data: CB ER SF ZA TH NK. Contributed reagents/materials/analysis
tools: SE. Wrote the paper: GN CB ER SF SW JF.
References
1. Wagers AJ, Allsopp RC, Weissman IL (2002) Changes in integrin expression are
associated with altered homing properties of Lin(-/lo)Thy1.1(lo)Sca-1(+)c-kit(+)
hematopoietic stem cells following mobilization by cyclophosphamide/granulo-
cyte colony-stimulating factor. Exp Hematol 30: 176–185.
2. Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, et al. (2002) Recruitment of
stem and progenitor cells from the bone marrow niche requires MMP-9
mediated release of kit-ligand. Cell 109: 625–637.
3. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL (2002)
Hematopoietic stem cells are uniquely selective in their migratory response to
chemokines. J Exp Med 195: 1145–1154.
4. Broxmeyer HE, Hangoc G, Cooper S, Campbell T, Ito S, et al. (2007)
AMD3100 and CD26 Modulate Mobilization, Engraftment, and Survival of
Hematopoietic Stem and Progenitor Cells Mediated by the SDF-1/CXCL12-
CXCR4 Axis. Ann N Y Acad Sci.
5. Hattori K, Heissig B, Rafii S (2003) The regulation of hematopoietic stem cell
and progenitor mobilization by chemokine SDF-1. Leuk Lymphoma 44:
575–582.
6. Glodek AM, Le Y, Dykxhoorn DM, Park SY, Mostoslavsky G, et al. (2007)
Focal adhesion kinase is required for CXCL12-induced chemotactic and pro-
adhesive responses in hematopoietic precursor cells. Leukemia.
7. Peled A, Kollet O, Ponomaryov T, Petit I, Franitza S, et al. (2000) The
chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on
immature human CD34(+) cells: role in transendothelial/stromal migration and
engraftment of NOD/SCID mice. Blood 95: 3289–3296.
8. Sugiyama T, Kohara H, Noda M, Nagasawa T (2006) Maintenance of the
hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone
marrow stromal cell niches. Immunity 25: 977–988.
9. Newman PJ (1997) The biology of PECAM-1. J Clin Invest 100: S25–S29.
10. Slieker WA, de Rijk-de Bruijn MF, Leenen PJ, van Ewijk W (1993) ER-MP12
antigen, a new cell surface marker on mouse bone marrow cells with thymus-
repopulating ability: I. Intrathymic repopulating ability of ER-MP12-positive
bone marrow cells. Int Immunol 5: 1093–1098.
11. Watt SM, Williamson J, Genevier H, Fawcett J, Simmons DL, et al. (1993) The
heparin binding PECAM-1 adhesion molecule is expressed by CD34+
hematopoietic precursor cells with early myeloid and B-lymphoid cell
phenotypes. Blood 82: 2649–2663.
12. de Bruijn MF, Slieker WA, van der Loo JC, Voerman JS, van Ewijk W, et al.
(1994) Distinct mouse bone marrow macrophage precursors identified by
differential expression of ER-MP12 and ER-MP20 antigens. Eur J Immunol 24:
2279–2284.
13. Ling V, Luxenberg D, Wang J, Nickbarg E, Leenen PJ, et al. (1997) Structural
identification of the hematopoietic progenitor antigen ER-MP12 as the vascular
endothelial adhesion molecule PECAM-1 (CD31). Eur J Immunol 27: 509–514.
14. Lee S, Im SA, Yoo ES, Nam EM, Lee MA, et al. (2000) Mobilization kinetics of
CD34(+) cells in association with modulation of CD44 and CD31 expression
during continuous intravenous administration of G-CSF in normal donors. Stem
Cells 18: 281–286.
15. Ferrero E, Belloni D, Contini P, Foglieni C, Ferrero ME, et al. (2003)
Transendothelial migration leads to protection from starvation-induced
apoptosis in CD34+CD14+ circulating precursors: evidence for PECAM-1
involvement through Akt/PKB activation. Blood 101: 186–193.
16. Bird IN, Taylor V, Newton JP, Spragg JH, Simmons DL, et al. (1999)
Homophilic PECAM-1(CD31) interactions prevent endothelial cell apoptosis
but do not support cell spreading or migration. J Cell Sci 112 ( Pt 12):
1989–1997.
17. Leavesley DI, Oliver JM, Swart BW, Berndt MC, Haylock DN, et al. (1994)
Signals from platelet/endothelial cell adhesion molecule enhance the adhesive
activity of the very late antigen-4 integrin of human CD34+ hemopoietic
progenitor cells. J Immunol 153: 4673–4683.
18. Yong KL, Watts M, Shaun TN, Sullivan A, Ings S, et al. (1998) Transmigration
of CD34+ cells across specialized and nonspecialized endothelium requires prior
activation by growth factors and is mediated by PECAM-1 (CD31). Blood 91:
1196–1205.
19. Voermans C, Rood PM, Hordijk PL, Gerritsen WR, van der Schoot CE (2000)
Adhesion molecules involved in transendothelial migration of human hemato-
poietic progenitor cells. Stem Cells 18: 435–443.
20. Dhanjal TS, Pendaries C, Ross EA, Larson MK, Protty MB, et al. (2007) A
novel role for PECAM-1 in megakaryocytokinesis and recovery of platelet counts
in thrombocytopenic mice. Blood 109: 4237–4244.
21. Wu Y, Welte T, Michaud M, Madri JA (2007) PECAM-1: A multifaceted
regulator of megakaryocytopoiesis. Blood.
22. Zicha D, Dunn GA, Brown AF (1991) A new direct-viewing chemotaxis
chamber. J Cell Sci 99 ( Pt 4): 769–775.
23. Petit I, Szyper-Kravitz M, Nagler A, Lahav M, Peled A, et al. (2002) G-CSF
induces stem cell mobilization by decreasing bone marrow SDF-1 and up-
regulating CXCR4. Nat Immunol 3: 687–694.
24. Mazo IB, von Andrian UH (1999) Adhesion and homing of blood-borne cells in
bone marrow microvessels. J Leukoc Biol 66: 25–32.
25. Ahmed Z, Dent RG, Leadbeater WE, Smith C, Berry M, et al. (2005) Matrix
metalloproteases: degradation of the inhibitory environment of the transected
optic nerve and the scar by regenerating axons. Mol Cell Neurosci 28: 64–78.
26. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC (1996) Isolation and
functional properties of murine hematopoietic stem cells that are replicating in
vivo. J Exp Med 183: 1797–1806.
27. Akashi K, Traver D, Miyamoto T, Weissman IL (2000) A clonogenic common
myeloid progenitor that gives rise to all myeloid lineages. Nature 404: 193–197.
28. Weissman IL, Anderson DJ, Gage F (2001) Stem and progenitor cells: origins,
phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev
Biol 17: 387–403.
29. Christensen JL, Weissman IL (2001) Flk-2 is a marker in hematopoietic stem cell
differentiation: a simple method to isolate long-term stem cells. Proc Natl Acad
Sci U S A 98: 14541–14546.
30. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, et al. (2005) SLAM
family receptors distinguish hematopoietic stem and progenitor cells and reveal
endothelial niches for stem cells. Cell 121: 1109–1121.
31. Nilsson SK, Debatis ME, Dooner MS, Madri JA, Quesenberry PJ, et al. (1998)
Immunofluorescence characterization of key extracellular matrix proteins in
murine bone marrow in situ. J Histochem Cytochem 46: 371–377.
32. Lenter M, Uhlig H, Hamann A, Jeno P, Imhof B, et al. (1993) A monoclonal
antibody against an activation epitope on mouse integrin chain beta 1 blocks
adhesion of lymphocytes to the endothelial integrin alpha 6 beta 1. Proc Natl
Acad Sci U S A 90: 9051–9055.
33. Bazzoni G, Shih DT, Buck CA, Hemler ME (1995) Monoclonal antibody 9EG7
defines a novel beta 1 integrin epitope induced by soluble ligand and manganese,
but inhibited by calcium. J Biol Chem 270: 25570–25577.
34. Nakamura Y, Tajima F, Ishiga K, Yamazaki H, Oshimura M, et al. (2004)
Soluble c-kit receptor mobilizes hematopoietic stem cells to peripheral blood in
mice. Exp Hematol 32: 390–396.
35. Nelissen I, Ronsse I, Van Damme J, Opdenakker G (2002) Regulation of
gelatinase B in human monocytic and endothelial cells by PECAM-1 ligation
and its modulation by interferon-beta. J Leukoc Biol 71: 89–98.
36. Enciso JM, Gratzinger D, Camenisch TD, Canosa S, Pinter E, et al. (2003)
Elevated glucose inhibits VEGF-A-mediated endocardial cushion formation:
modulation by PECAM-1 and MMP-2. J Cell Biol 160: 605–615.
37. Geiger H, True JM, de Haan G, Van Zant G (2001) Age- and stage-specific
regulation patterns in the hematopoietic stem cell hierarchy. Blood 98:
2966–2972.
38. de Haan G, Bystrykh LV, Weersing E, Dontje B, Geiger H, et al. (2002) A
genetic and genomic analysis identifies a cluster of genes associated with
hematopoietic cell turnover. Blood 100: 2056–2062.
39. Avecilla ST, Hattori K, Heissig B, Tejada R, Liao F, et al. (2004) Chemokine-
mediated interaction of hematopoietic progenitors with the bone marrow
vascular niche is required for thrombopoiesis. Nat Med 10: 64–71.
40. Kopp HG, Avecilla ST, Hooper AT, Rafii S (2005) The bone marrow vascular
niche: home of HSC differentiation and mobilization. Physiology (Bethesda ) 20:
349–356.
41. Yang FC, Atkinson SJ, Gu Y, Borneo JB, Roberts AW, et al. (2001) Rac and
Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and
mobilization. Proc Natl Acad Sci U S A 98: 5614–5618.
42. McQuibban GA, Butler GS, Gong JH, Bendall L, Power C, et al. (2001) Matrix
metalloproteinase activity inactivates the CXC chemokine stromal cell-derived
factor-1. J Biol Chem 276: 43503–43508.
43. Katayama Y, Hidalgo A, Furie BC, Vestweber D, Furie B, et al. (2003) PSGL-1
participates in E-selectin-mediated progenitor homing to bone marrow: evidence
for cooperation between E-selectin ligands and alpha4 integrin. Blood 102:
2060–2067.
44. Papayannopoulou T (2004) Current mechanistic scenarios in hematopoietic
stem/progenitor cell mobilization. Blood 103: 1580–1585.
45. Graesser D, Solowiej A, Bruckner M, Osterweil E, Juedes A, et al. (2002) Altered
vascular permeability and early onset of experimental autoimmune encephalo-
myelitis in PECAM-1-deficient mice. J Clin Invest 109: 383–392.
46. Maas M, Stapleton M, Bergom C, Mattson DL, Newman DK, et al. (2005)
Endothelial cell PECAM-1 confers protection against endotoxic shock.
Am J Physiol Heart Circ Physiol 288: H159–H164.
47. Wong MX, Hayball JD, Hogarth PM, Jackson DE (2005) The inhibitory co-
receptor, PECAM-1 provides a protective effect in suppression of collagen-
induced arthritis. J Clin Immunol 25: 19–28.
PECAM-1 Regulates HSC Numbers
PLoS ONE | www.plosone.org 9 June 2008 | Volume 3 | Issue 6 | e2338
48. Newman PJ, Newman DK (2003) Signal transduction pathways mediated by
PECAM-1: new roles for an old molecule in platelet and vascular cell biology.
Arterioscler Thromb Vasc Biol 23: 953–964.
49. Sagawa K, Kimura T, Swieter M, Siraganian RP (1997) The protein-tyrosine
phosphatase SHP-2 associates with tyrosine-phosphorylated adhesion molecule
PECAM-1 (CD31). J Biol Chem 272: 31086–31091.
50. Pumphrey NJ, Taylor V, Freeman S, Douglas MR, Bradfield PF, et al. (1999)
Differential association of cytoplasmic signalling molecules SHP-1, SHP-2, SHIP
and phospholipase C-gamma1 with PECAM-1/CD31. FEBS Lett 450: 77–83.
51. Jackson DE, Ward CM, Wang R, Newman PJ (1997) The protein-tyrosine
phosphatase SHP-2 binds platelet/endothelial cell adhesion molecule-1
(PECAM-1) and forms a distinct signaling complex during platelet aggregation.
Evidence for a mechanistic link between PECAM-1- and integrin-mediated
cellular signaling. J Biol Chem 272: 6986–6993.
52. Hua CT, Gamble JR, Vadas MA, Jackson DE (1998) Recruitment and
activation of SHP-1 protein-tyrosine phosphatase by human platelet endothelial
cell adhesion molecule-1 (PECAM-1). Identification of immunoreceptor
tyrosine-based inhibitory motif-like binding motifs and substrates. J Biol Chem
273: 28332–28340.
53. Ilan N, Cheung L, Miller S, Mohsenin A, Tucker A, et al. (2001) Pecam-1 is a
modulator of stat family member phosphorylation and localization: lessons from
a transgenic mouse. Dev Biol 232: 219–232.
54. Ilan N, Mohsenin A, Cheung L, Madri JA (2001) PECAM-1 shedding during
apoptosis generates a membrane-anchored truncated molecule with unique
signaling characteristics. FASEB J 15: 362–372.
55. Luu NT, Rainger GE, Buckley CD, Nash GB (2003) CD31 regulates direction
and rate of neutrophil migration over and under endothelial cells. J Vasc Res 40:
467–479.
56. Rainger GE, Buckley C, Simmons DL, Nash GB (1997) Cross-talk between cell
adhesion molecules regulates the migration velocity of neutrophils. Curr Biol 7:
316–325.
57. Reedquist KA, Ross E, Koop EA, Wolthuis RM, Zwartkruis FJ, et al. (2000)
The small GTPase, Rap1, mediates CD31-induced integrin adhesion. J Cell Biol
148: 1151–1158.
PECAM-1 Regulates HSC Numbers
PLoS ONE | www.plosone.org 10 June 2008 | Volume 3 | Issue 6 | e2338
